Altos Labs was launched with the goal of transforming medicine by programming cell renewal

Altos’ executive team will consist of Hal BarronMD (new CEO), Rick KlausnerMD (Chief Scientist and Founder), Hans Bishop (President and Founder), and Anne Lee Carlon, Ph.D. (Head of Operations). Hal Barron He is currently Head of Research and Development and Chief Scientific Officer at GSK and will join Altos as CEO and Co-Chair of the Board of Directors August 1, 2022. Klausner was a former director of the National Cancer Institute and an entrepreneur, Bishop was the former CEO of GRAIL and Juno Therapeutics, and Lee Carlon was a former senior vice president of Genentech.

Altos will initially be based in the United States at San Francisco Bay Area And San Diego, and in the UK in Cambridge. The company will also have significant cooperation in Japan. Within these geographical areas, the activity will be organized across the Institutes of Science and the Institute of Medicine. The Altos Institutes of Science will pursue deep scientific questions and combine their findings into a single collaborative research effort. The Altos Institute of Medicine will capture the knowledge generated about cell health and programming to develop transformative drugs.

The three Altos Institutes of Science will be directed by Juan Carlos Izpisua Belmonte, Ph.D., wolf rick, MD, and Peter Walter, Ph.D. Thor Grable, Ph.D., will serve as the global head of computational sciences, artificial intelligence, and machine learning. Prior to joining Altos, Izpisua Belmonte was Professor and Chair at the Salk Institute, Reik was Director of the Babraham Institute and is Professor Emeritus at Cambridge UniversityWalter was a professor at University of California, San Francisco (UCSF) and an investigator at the Howard Hughes Medical Institute. Graepel previously worked as Head of Research at Google DeepMind and Professor at University College London. Within the institutes of science, an extraordinary group of principal investigators (PIs) will collaboratively pursue many aspects of cell health and programming. A complete list of PIs is found in

Altos’ board of directors and advisors includes Nobel laureates and scientific leaders. He will chair the council jointly with Rick KlausnerAnd Hans Bishop, And Hal Barron (Current Director and incoming Co-Chairman) The following members of the Board of Directors include: Frances Arnold, Ph.D. (Linus Pauling Professor of Chemical Engineering, Bioengineering, and Biochemistry at California Institute of Technology and Nobel Laureate), Hal BarronJennifer Doudna, MD (Chief Scientific Officer and Head of Research and Development for GSK), Jennifer Doudna (Li Ka-shing Counsellor President and Professor of Chemistry, Molecular and Cell Biology at University of California, Berkeley, Head of the Innovative Genomics Institute and Nobel Laureate) Maria Liptin, PhD (President of the European Research Council), Robert Nielsen (Co-founder and General Manager, ARCH Venture Partners), Rajiv Shah, MD (chairman of the Rockefeller Foundation), and David Baltimore, Ph.D. (Honorary Chair and Judge Professor Shirley Hofstadler biology in California Institute of Technology and Nobel Laureate), as principal independent director. Shinya YamanakaMD, PhD (Director of the Center for iPS Cell Research and Application at Kyoto University and Nobel Laureate), as Altos’ unpaid senior scientific advisor, supervising research activities at Japan.

“I am deeply honored to have this once in a lifetime opportunity to lead such a unique company with a transformative mission to reverse disease,” he said. Hal Barron. “This is clear from the work Shinya Yamanakaand many others since his initial discoveries, that cells have the ability to regenerate, reset their epigenetic clocks and erase damage caused by a myriad of stressors. These ideas, along with major advances in a number of transformative technologies, have inspired Altos to reimagine medical treatments where disease can be reversed for patients of any age.”

Altos is designed to combine the best features of academia and industry – from academia, freedom to pursue the most challenging problems in biology, from industry focus on a common mission, ability to foster deep collaboration, passion and commitment to transforming science in pharmaceuticals.

“Altos seeks to decode cell-renewal programming pathways to create an entirely new approach to medicine, based on emerging concepts of cellular health,” he said. Rick Klausner. “Fantastic work over the past few years beginning with defining cellular health and the mechanisms behind it, along with the ability to effectively and safely reprogram cells and tissues via regeneration pathways, opens this new landscape in future medicine. Altos begins with several leading scientists who have pioneered This new science. Together, we are building a company where many of the world’s best scientists can collaborate internally and externally and advance their research with speed, mission and special project focus. Our success will depend on a culture of intense collaboration, enthusiasm, and openness.”

“Building a company with extraordinary ambition requires extraordinary people,” he said. Hans Bishop. “It will also require building a culture of innovation that brings out the best in people from very diverse backgrounds. We aim to amplify the best traits of academia and companies with the goal of accelerating problem solving. I am excited to join a team with such an inspiring mission and inner ambition to build a company where we can all say we are doing our best. our effort.”

Frances ArnoldM., Board Member and Nobel Laureate, believes “Altos is introducing an entirely new research and development paradigm that targets humanity’s oldest problems, slowing and eventually even reversing the effects of disease. This brilliant team is poised to discover the secrets of cellular health and transform the way we think about it.” Disease. It is more time than ever to restructure our approach to health by understanding, slowing, and even reversing the processes that lead to disease and death.”

“As a geneticist and evolutionary biologist, I find great promise in the emerging recognition that metabolic control of cell health critically contributes to an organism’s ability to withstand major systemic insults from congenital and infectious diseases to stress and aging,” said Maria Leptin, Member of the Board and Chair of the IER . “As a committed believer in curiosity-driven research, I welcome a broad approach to trying to understand the basic cellular principles involved in returning a stressed organism to a state of healthy homeostasis.”

Shinya YamanakaSenior Scientific Adviser and Nobel Laureate said: “I am delighted to be part of Altos and I believe it is one of the most important and exciting new global scientific endeavors. The possibility of programming regeneration has recently become a scientific fact and has the potential to enable us to approach human disease in an entirely new way. I will help scientists in Japan to work in this exciting field.

“I am honored to serve as the lead independent director of the newly formed Altos Laboratories,” he said. David BaltimoreBoard member and Nobel laureate. “Altos will build on the remarkable evolving understanding of cell changes as they participate in the myriad processes of the human body over the course of their life. The goal of Altos is to reverse the ravages of disease and aging that lead to disability and death, revitalizing and prolonging quality of life. Altos will provide an unparalleled environment for collaborative discovery. It has already attracted a group of the most impressive researchers to the daunting task of reversing poor health and taking medicine in a new direction.”

About Scientific Leadership at Altos

He will lead the Altus Bay District Institute of Science Peter Walter, Ph.D., whose research has focused on advancing the molecular understanding of how cells control the quality of proteins and organelles during homeostasis and stress. Dr. Walter has received numerous awards, including the Shaw Prize, the Lasker Prize for Basic Medical Research, the Vilcek Prize for Biomedical Sciences, and the Breakthrough Prize in the Life Sciences. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Inventors. Prior to joining Altos, Dr. Walter was a Professor in the Department of Biochemistry/Biophysics at University of California, San Francisco (UCSF) and an investigator at the Howard Hughes Medical Institute.

The Altos San Diego Institute of Science will be directed by Juan Carlos Izpisua Belmonte, Ph.D. Dr. Izbichoa Belmonte is a pioneer in the field of regenerative medicine. He has developed many strategies to improve health, including regeneration of tissues and organs, and regeneration of cells and organisms. He has received the National Science Foundation Creativity Award, the National Institutes of Health Pioneers Award, the William Clinton Presidential Award, the Bio Scholar Award, the Castilla-La Mancha Gold Medal, and the Nobel Laureate Roger Guillemin Chair. Prior to Altos, Dr. Izpisua Belmonte was Professor in the Gene Expression Laboratory and Roger Guillemin Chair at the Salk Institute in La Jolla, California.

He will lead the Altus Cambridge (UK) Institute of Science wolf rick, Doctor of Medicine. Dr. Rick is a pioneer in the epigenetic reprogramming of mammalian cells, and is Professor Emeritus of Epigenetics at Cambridge UniversityMost recently, he held the position of Director of the Abraham Institute in Cambridge. He received the Wellcome Prize in Physiology and is a member of the European Organization for Molecular Biology and the European Academy, and a Fellow of the Academy of Medical Sciences and the Royal Society.

Altos will also support activities in Japan, guided Shinya Yamanaka, MD, PhD, who will be Altos’ unpaid senior scientific advisor. Dr. Yamanaka is among the world’s leading bodies in the field of stem cell science, and is the recipient of the 2012 Nobel Prize in Physiology or Medicine for his discovery of induced pluripotent stem cells. He is currently the Director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University He is a senior investigator at the Gladstone Institutes.

In all aspects of Altos, there will be a commitment to computational science, machine learning and artificial intelligence through the activities he leads Thor Grable, Ph.D. Graepel was recently lead research at Google DeepMind and Head of Machine Learning at University College London, and is one of the masterminds on how to build smarter systems and agents that learn from experience.

About Altos Labs

Altos Labs™ (Altos™) is a biotechnology company focused on programming cell renewal to restore cell health and elasticity, with the goal of reversing disease to transform medicine. The company includes a community of leading scientists, clinicians, and leaders from academia and industry who work together to achieve this common mission.

Altos has operations in San Francisco Bay Area And San Diego, and in Cambridge, United Kingdom, with great cooperation in Japan.

visit Learn more about Altos, including a full list of our top scientists and leaders.

Media contact

Morgan Warners
Finsbury Glover Hering
[email protected]

Kim James
Finsbury Glover Hering
[email protected]

SOURCE Altos Labs


Leave a Comment